Whitelogolarge.jpg
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Aaron’s Company, Inc. – AAN
June 26, 2024 10:30 ET | Monteverde & Associates PC
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022...
Whitelogolarge.jpg
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Aaron’s Company, Inc. – AAN
June 20, 2024 12:35 ET | Monteverde & Associates PC
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022...
tiziana-logo.png
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
April 19, 2024 07:00 ET | Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
tiziana-logo.png
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 18, 2024 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
April 12, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
tiziana-logo.png
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 11, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology
AB Science - Résumé
AB Science - Résumé de la présentation dans la SLA à la réunion annuelle 2023 de l'AAN
April 27, 2023 14:41 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE RESUME LA PRESENTATION FAITE DU MASITINIB DANS LA DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE À LA RÉUNION ANNUELLE 2023 DE L'AMERICAN ACADEMY OF NEUROLOGY, INCLUANT...
AB Science - Summary
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
April 27, 2023 14:41 ET | AB Science
PRESS RELEASE AB SCIENCE SUMMARIZES THE PRESENTATION ON MASITTINIB IN AMYOTROPHIC LATERAL SCLEROSIS MADE AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL...
Axsome Logo.png
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 21, 2023 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
April 19, 2023 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...